BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 12.90B +34.8% |
| Revenue (ttm) | 713.07M +202.4% |
| Net Income | -691.87M |
| EPS | -3.57 |
| Shares Out | 195.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,597,122 |
| Open | 66.38 |
| Previous Close | 66.61 |
| Day's Range | 65.82 - 67.16 |
| 52-Week Range | 50.50 - 93.42 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 109.10 (+65.38%) |
| Est. Earnings | Oct 28, 2026 |
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ... [Read more]
Financial Performance
In 2025, BridgeBio Pharma's revenue was $502.08 million, an increase of 126.26% compared to the previous year's $221.90 million. Losses were -$724.93 million, 35.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price target is $109.1, which is an increase of 65.38% from the latest price.
News
BridgeBio Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
The forum highlighted a robust late-stage portfolio with four major product launches expected globally within 18 months, driven by strong clinical data and real-world evidence. Attruby leads with blockbuster sales and new data, while three additional therapies target high unmet needs and billion-dollar markets.
BridgeBio Pharma announces results from trial of tafamidis in ATTR-CM
BridgeBio Pharma (BBIO) announced results published in Cardiology and Therapy from the first peer-reviewed, contemporary real-world comparative effectiveness retrospective study of transthyretin, TTR,...
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabilizers in ATTR-CM using U.S. claims data, acoramidis was associated with a statistically and clinica...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic cond...
BridgeBio Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and AI are driving operational improvements and partnerships, while regulatory wins and differentiated clinical data fuel strong growth for key products. Attruby leads with first-line market expansion and premium pricing, and multiple pipeline launches are set to drive profitability by 2028.
BridgeBio Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Multiple late-stage assets are nearing launch, with Attruby leading in ATTR-CM and strong differentiation supported by clinical and real-world data. BBP-418 and infigratinib show robust efficacy and market potential, while global commercialization is advancing with a solid financial base and strategic MFN agreement.
BridgeBio Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference
The business is experiencing strong growth with Attruby and anticipates further acceleration from three major drug launches in 2027. Differentiation in ATTR-CM, robust pipeline data, and targeted launch strategies for rare diseases underpin confidence in sustained expansion and capital deployment for future innovation.
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
BridgeBio Pharma presents new exploratory analyses from PROPEL 3 at ESPE
BridgeBio Pharma (BBIO) presented new exploratory analyses from PROPEL 3, the global Phase 3 study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends b...
Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on devel...
BridgeBio Pharma files $500M mixed securities shelf
17:26 EDT BridgeBio Pharma (BBIO) files $500M mixed securities shelf
BridgeBio Pharma price target raised to $110 from $96 at Mizuho
Mizuho raised the firm’s price target on BridgeBio Pharma (BBIO) to $110 from $96 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on devel...
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
- This voluntary agreement expands access for Medicaid patients to BridgeBio's currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rar...
BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study
BridgeBio Pharma (BBIO) presented new analyses from the Phase 3 ATTRibute-CM study of Attruby in transthyretin amyloid cardiomyopathy, ATTR-CM, including the cardiac magnetic resonance imaging, CMR, s...
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showin...
BridgeBio Pharma Slides: Corporate presentation
BridgeBio Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 30, 2026.
BridgeBio Pharma doses first patient in ASCEND-ATTR trial
BridgeBio Pharma (BBIO) announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study designed to further characterize the long-term effects of acoramidis on the improvement o...
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with eviden...
BridgeBio Pharma participates in a conference call with Cantor
Cantor Fitzgerald holds a conference call with management on August 28 at 10 am. Webcast Link
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi...
BridgeBio Oncology announces 5M common stock offering for holders
BridgeBio Pharma (BBIO) announced the launch of a secondary public offering of 5M shares of its common stock by the selling stockholder KKR Genetic Disorder. The company is not selling…
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
- The transaction supports the evolution of the Company's shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ...